- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05647733
Restrictive Fluid Management In Liver Transplantation (REFIL) (REFIL)
Effects of an Intraoperative Low-splanchnic Blood Volume Restrictive Fluid Management Strategy Compared to a Cardiac Output Optimized Liberal Fluid Management Strategy on Postoperative Outcomes in Liver Transplantation
Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial
Study population: Patients with end-stage liver disease undergoing a liver transplantation not meeting any exclusion criteria.
Primary endpoint: The primary feasibility endpoint is an overall recruitment rate ≥ 4 patients/month across all three participating sites.
Secondary endpoint: The secondary feasibility endpoints are a protocol adherence > 90%, a 30-day (or hospital discharge) and 6-month outcome measurement > 90%, and a mean difference in total intraoperative volume received (crystalloids and colloids combined) > 1000 ml between groups.
Study intervention: Low splanchnic blood volume restrictive fluid management strategy (intervention). A phlebotomy, performed prior to dissection and transfused back after graft reperfusion, combined with a hemodynamic goal-directed restrictive fluid management strategy
Optimized cardiac-output liberal fluid management strategy (control) A hemodynamic goal-directed liberal fluid management strategy that optimizes cardiac output throughout surgery
Study Overview
Status
Conditions
Detailed Description
MAIN OBJECTIVE The main objective of the REFIL-1 pilot study is to establish the feasibility (recruitment, adherence, outcome measurement) of conducting a Canadian multicentre randomized controlled trial comparing an intraoperative low-splanchnic blood volume restrictive fluid management strategy to a cardiac output optimised liberal fluid management strategy in adult LT for ESLD. The hypothesis is that a Canadian multicentre clinical trial is feasible.
SECONDARY OBJECTIVES The overarching objective of the ReFIL (Restrictive Fluid management In Liver transplantation) research program, which will be answered in a future large-scale trial, regards the efficacy of the proposed interventional strategy to improve postoperative outcomes in LT.
TERTIARY OBJECTIVES Our tertiary objective is to measure the cost-effectiveness of the proposed intervention based on the composite outcome of any severe postoperative complications and graft loss.
DESIGN AND STUDY POPULATION This study a multicentre internal pilot parallel arm randomized trial comparing two intraoperative hemodynamic and splanchnic blood volume management strategies in LT recipients.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: François-Martin Carrier, MD
- Phone Number: 514-890-8000
- Email: francois.martin.carrier.med@ssss.gouv.qc.ca
Study Contact Backup
- Name: Martine Lebrasseur, RN
- Phone Number: 514-890-8000
- Email: martine.lebrasseur.chum@ssss.gouv.qc.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6G 2V4
- Not yet recruiting
- London Health Sciences Centre
-
Contact:
- Nelson Javier Gonzalez Valencia, MD
- Phone Number: (519) 661-2111
- Email: nelson.gonzalezvalencia@lhsc.on.ca
-
Principal Investigator:
- Nelson Javier Gonzalez Valencia, MD
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 0C1
- Recruiting
- Centre Hospitalier de l'Universite de Montreal (CHUM)
-
Contact:
- François-Martin Carrier, MD
- Phone Number: 514-890-8000
- Email: francois.martin.carrier.med@ssss.gouv.qc.ca
-
Principal Investigator:
- François-Martin Carrier, MD
-
Sub-Investigator:
- Michael Chassé, MD
-
Montréal, Quebec, Canada, H4A 3J1
- Not yet recruiting
- McGill University Health Centre
-
Contact:
- Stanislas Kandelman, MD
- Phone Number: (514)934-1934
- Email: stanislas.kandelman.med@ssss.gouv.qc.ca
-
Principal Investigator:
- Stanilas Kandelman, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any adult patient ≥ 18 years of age undergoing liver transplantation for ESLD.
Exclusion Criteria:
- Patients undergoing LT for an indication other than ESLD such as acute liver failure, liver cancer without ESLD, retransplantation, amyloid neuropathy or any other indication not associated with ESLD.
- Patients undergoing a combined liver and lung or liver and heart transplantation.
- Patients with any of the following conditions:
- severe chronic renal failure (GFR < 15 ml/minute/1.73 m2 [CKD-EPI equation] or already on RRT);
- severe anemia (hemoglobin level < 80 g/L);76,93,109
- hemodynamic instability (norepinephrine equivalent > 10 ug/min).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Restrictive group: Low splanchnic blood volume Restrictive fluid management strategy
The intervention group is targeted at lowering splanchnic blood volume using a phlebotomy and restricting fluid infusion, individualized to the physiological needs of this population and the distinct LT surgical phases.
The strategy will first consist of performing a phlebotomy without fluid replacement at the start of surgery.We will combine it with fluid restriction to prevent excessive fluid administration and its effect on splanchnic blood volume and blood loss, combined with the effect of the phlebotomy, as well as to limit fluid overload, as previously reported.
Fluid will be administered to compensate blood loss and treat severe hemodynamic instability.The phlebotomy will be transfused back at the beginning of the reperfusion phase where fluid management will be based on a goal-directed therapy (GDT) using either PPV or SV, as in the control group.
|
Hemodynamic goal-directed restrictive fluid management strategy.
Other Names:
Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
|
Active Comparator: Liberal group: Optimized cardiac output liberal fluid management strategy
The control group will receive a liberal intraoperative fluid management strategy optimizing cardiac output throughout the surgery.
It will consist of administering 250 mL fluid boluses until SV stops to increase by more than 10% or until PPV is below 12%, a dynamic indicator of fluid responsiveness validated in many surgical populations, including ESLD patients undergoing a LT.This strategy is informed by data from recent clinical trials on benefits of GDT in major surgery, data on strategies used in major surgery, liver resection or LT and our survey on current practice.
|
Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment rate
Time Frame: 18 months (at study level)
|
Overall recruitment rate ≥ 4 patients/month (across all sites)
|
18 months (at study level)
|
Adherence
Time Frame: At time of surgery
|
Protocol adherence > 90%, defined using a questionnaire
|
At time of surgery
|
Hospital outcome measurement completeness
Time Frame: At 30 days (or hospital discharge) after surgery
|
A 30 days or hospital discharge outcome measurement > 90%
|
At 30 days (or hospital discharge) after surgery
|
6-month outcome measurement completeness
Time Frame: 6 months after surgery
|
6-month outcome measurement > 90%
|
6 months after surgery
|
Mean difference in total volume received
Time Frame: At time of surgery
|
A mean difference in total volume received (crystalloids and colloids combined) > 1000 ml between groups.
|
At time of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severe complications and graft lost
Time Frame: Up to 30 days or hospital discharge
|
Composite incidence of severe complication (Dindo-Clavien III or more) or graft lost (retransplantation or death)
|
Up to 30 days or hospital discharge
|
Intraoperative blood loss
Time Frame: End of surgery
|
Intraoperative blood loss in mL
|
End of surgery
|
Intraoperative and perioperative blood product transfusions
Time Frame: From randomization up to 30 days or hospital discharge, whichever comes first
|
Total number of transfused units of labile and non-labile blood products (red blood cells, plasma, platelets, cryoprecipitates, fibrinogen, prothrombin complex concentrates)
|
From randomization up to 30 days or hospital discharge, whichever comes first
|
7-day quality of recovery
Time Frame: 7 days after surgery
|
7-day quality of recovery measured using the QoR-15 (Quality of Recovery) tool
|
7 days after surgery
|
7-day graft dysfunction
Time Frame: 7 days after surgery
|
7-day graft dysfunction (definition as reported by Olthoff et al.)
|
7 days after surgery
|
7-day AKI (grade 2 or 3)
Time Frame: 7 days after surgery
|
7-day AKI grade 2 or 3 using the KDIGO (Kidney Disease: Improving Global Outcomes) definition
|
7 days after surgery
|
Any complication
Time Frame: From randomization up to 30 days or hospital discharge, whichever comes first
|
Any of the following complications, graded according to the Dindo-Clavien classification system: hemorrhagic, graft related, pulmonary, infectious or thromboembolic.
|
From randomization up to 30 days or hospital discharge, whichever comes first
|
Any other severe complication
Time Frame: From randomization up to 30 days or hospital discharge, whichever comes first
|
Any other severe complication (Dindo-Clavien III or more)
|
From randomization up to 30 days or hospital discharge, whichever comes first
|
Organ dysfunction and support
Time Frame: 30 days
|
30-day organ support free days, using a recognized definition (as reported by Heyland et al.)
|
30 days
|
Intensive care unit (ICU) length of stay
Time Frame: From randomization up to hospital discharge (ascertained up to end of follow-up at 1 year)
|
Total duration of stay (days) in the intensive care unit (ICU)
|
From randomization up to hospital discharge (ascertained up to end of follow-up at 1 year)
|
Hospital length of stay
Time Frame: From randomization up to hospital discharge (ascertained up to end of follow-up at 1 year)
|
Total duration of stay (days) in the hospital
|
From randomization up to hospital discharge (ascertained up to end of follow-up at 1 year)
|
Quality of life (QoL)
Time Frame: 6 & 12 months after surgery
|
Quality of life (QoL) using the SF-36 tool
|
6 & 12 months after surgery
|
Hospital readmissions
Time Frame: From randomization up to 1 year after surgery
|
Hospital readmissions
|
From randomization up to 1 year after surgery
|
Graft complications
Time Frame: From randomization up to 1 year after surgery
|
Graft complications
|
From randomization up to 1 year after surgery
|
Survival
Time Frame: From randomization up to 1 year after surgery
|
Survival
|
From randomization up to 1 year after surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Francois-Martin Carrier, MD, Centre Hospitalier Universite de Montreal
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-11173
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
-
Rennes University HospitalCompletedLiver Transplantation | Kidney TransplantationFrance
Clinical Trials on Low splanchnic blood volume restrictive fluid management strategy
-
Tel-Aviv Sourasky Medical CenterUnknownSepsis | Acute Lung Injury (ALI) | Acure Respiratory Distress Syndrome (ARDS)Israel
-
Postgraduate Institute of Medical Education and...TerminatedAcute Respiratory Distress Syndrome (ARDS)India
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Respiratory Distress Syndrome, AdultUnited States, Canada